Your browser doesn't support javascript.
loading
A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia.
Li, Chunrui; Cao, Wenyue; Que, Yimei; Wang, Qiuxiang; Xiao, Yi; Gu, Chaojiang; Wang, Di; Wang, Jue; Jiang, Lijun; Xu, Hao; Xu, Jinhuan; Zhou, Xiaoxi; Hong, Zhenya; Wang, Na; Huang, Liang; Zhang, Shangkun; Chen, Liting; Mao, Xia; Xiao, Min; Zhang, Wei; Meng, Li; Cao, Yang; Zhang, Tongcun; Li, Jian; Zhou, Jianfeng.
Afiliação
  • Li C; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Cao W; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China.
  • Que Y; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Wang Q; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China.
  • Xiao Y; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Gu C; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China.
  • Wang D; Wuhan No.1 Hospital, Wuhan, Hubei, China.
  • Wang J; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Jiang L; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China.
  • Xu H; College of Life Science and Health, Wuhan University of Science and Technology, Wuhan, Hubei, China.
  • Xu J; Wuhan Bio-Raid Biotechnology Co., Ltd., Wuhan, Hubei, China.
  • Zhou X; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Hong Z; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China.
  • Wang N; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Huang L; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China.
  • Zhang S; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Chen L; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China.
  • Mao X; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Xiao M; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China.
  • Zhang W; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Meng L; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China.
  • Cao Y; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Zhang T; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China.
  • Li J; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Zhou J; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China.
Clin Transl Med ; 11(3): e346, 2021 03.
Article em En | MEDLINE | ID: mdl-33784005
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfócitos T / Leucemia Plasmocitária / Imunoterapia Adotiva / Antígeno de Maturação de Linfócitos B / Receptores de Antígenos Quiméricos / Mieloma Múltiplo Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Transl Med Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfócitos T / Leucemia Plasmocitária / Imunoterapia Adotiva / Antígeno de Maturação de Linfócitos B / Receptores de Antígenos Quiméricos / Mieloma Múltiplo Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Transl Med Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China País de publicação: Estados Unidos